
|Videos|January 29, 2014
The Design and Results of TRINOVA-1
Author(s)Bradley J. Monk, MD
Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.
Advertisement
Clinical Pearls
Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.
- The TRINOVA-1 trial studied trebananib plus paclitaxel versus placebo plus paclitaxel in 919 patients who had recurrent ovarian cancer and up to three prior lines of therapy
- Trebananib plus weekly paclitaxel improved the hazard ratio for progression by 0.66
- The combination also improved response rate and the survival data, although not yet mature, showed a hazard ratio of 0.86
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































